-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

|Articles|August 16, 2019

Improving the Economic Burden of Ankylosing Spondylitis: Targeting IL-17/IL-23 Pathways

https://www.pharmacytimes.org/on-demand/improving-the-economic-burden-of-ankylosing-spondylitis-targeting-il-23il-17-pathways

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Heart examination | Image credit: Ngampol - stock.adobe.com

ATTR-CM Incidence, Prevalence Rose Sharply in the US

ByPearl Steinzor

June 23rd 2026

Managed Care Cast Director's Cut

Rewriting the AML Treatment Playbook: Tina Bhatnagar, DO

ByMaggie L. Shaw,Bhavana (Tina) Bhatnagar, DO

June 23rd 2026

maternal health | Image credit: Pituk - stock.adobe.com

CV Health in Pregnancy Linked to Developmental Delay in Children

ByPearl Steinzor

June 23rd 2026

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

ByBrooke McCormick

June 23rd 2026

Open laptop with FDA approval overlay.| Image Credit: Pakin-stock.adobe.com.jpeg

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

ByElla Hohmann, MS

June 23rd 2026

Trending on AJMC

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC